Quote | Longeveron Inc. (NASDAQ:LGVN)
Last: | $1.29 |
---|---|
Change Percent: | -0.75% |
Open: | $1.35 |
Close: | $1.29 |
High: | $1.3504 |
Low: | $1.27 |
Volume: | 326,488 |
Last Trade Date Time: | 05/16/2024 03:00:00 am |
News | Longeveron Inc. (NASDAQ:LGVN)
2024-05-15 08:31:48 ET More on Longeveron Longeveron announces board transitions Longeveron stock rallies 85% on Alzheimer's presentation (update) Seeking Alpha’s Quant Rating on Longeveron Historical earnings data for Longeveron Read the ful...
Phase 2b clinical trial evaluating Lomecel-B TM in rare pediatric disease HLHS on track for completing enrollment by end of 2024 Data from Phase 2a clinical trial evaluating Lomecel-B TM in Alzheimer’s Disease selected for Featured Research Oral Presentation at 2024 Alzheimer...
Message Board Posts | Longeveron Inc. (NASDAQ:LGVN)
Subject | By | Source | When |
---|---|---|---|
institutions loading up,nhod,ka-freaking-BOOM!!! | 81vette | investorshub | 05/09/2023 4:29:36 PM |
ZERO BORROW,just now out of shares,1st time in | 81vette | investorshub | 05/09/2023 4:06:18 PM |
5m float,short 166k shares,197Xs ave volume should push | 81vette | investorshub | 05/09/2023 2:45:28 PM |
MomentumIts now last up | Roadtojourney | investorshub | 05/08/2023 8:13:19 PM |
$LGVN Price gaining last trade up | subslover | investorshub | 05/08/2023 4:36:46 PM |
News, Short Squeeze, Breakout and More Instantly...
Longeveron Inc. Company Name:
LGVN Stock Symbol:
NASDAQ Market:
Phase 2b clinical trial evaluating Lomecel-B TM in rare pediatric disease HLHS on track for completing enrollment by end of 2024 Data from Phase 2a clinical trial evaluating Lomecel-B TM in Alzheimer’s Disease selected for Featured Research Oral Presentation at 2024 Alzheimer...
Longeveron (NASDAQ: LGVN) , a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, is reporting changes on its board of directors. The following transitions on the board have been announced: Richard Kender, retired SVP of bu...
Richard Kender, retired SVP of Business Development and Corporate Licensing for Merck & Co., Inc., has been appointed to the Longeveron Board...